Ballicules.com

Lacosamide

VIMPAT

Pronunciation: la-KOE-sa-mide (VIM-pat)

Lacosamide ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Lacosamide ballicule
Lacosamide VIMPAT mascot mnemonic cartoon
Visual mnemonic: Lacosamide mascot
“Lacrosse Vampire”

What it isEnhancer of slow sodium channel inactivation; focal seizures.

Why this oneA mechanism distinct from the fast-inactivation blockers, so it adds where they have failed, with few interactions and an IV form.

What limits itPR interval prolongation, so caution with AV block. Dizziness and diplopia are dose-limiting; Schedule V.

Lacosamide molecular structure (skeletal formula)
Molecular structure: Lacosamide

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Partial-onset seizures — monotherapyadult (≥17 yr)100 mg BID200 mg BID
Partial-onset seizures — adjunctive; primary generalized tonic-clonic (≥4 yr)adult (≥17 yr)50 mg BID200 mg BID
Partial-onset / PGTC seizurespediatric 1 month to <17 yrweight-based, twice daily (per Table 1)

Titration Increase based on response/tolerability no more frequently than once per week

Renal Severe renal impairment (CLCR <30 mL/min) or ESRD: reduce maximum dosage by 25%

Hepatic Mild-to-moderate hepatic impairment: reduce maximum dosage by 25%; severe hepatic impairment: not recommended

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy Based on animal data, may cause fetal harm; human data insufficient

Lactation Present in human milk; monitor breastfed infants for excess sedation

Cost

Lacosamide (VIMPAT)
What pharmacies pay · NADAC 9/30/26
Strength#/mogeneric $/moCostPlus
50 mgtab60 BID$7.12not offered
100 mgtab60 BID$10.46not offered
150 mgtab60 BID$13.28not offered
200 mgtab60 BID$14.88not offered

Other forms: Lacosamide ER (MOTPOLY XR)

Generic entry2022

NO BOXED WARNINGS

Principal riskPR prolongation and dizziness

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability1 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilitySedation, dizziness and agent-specific rash, behavioral, hepatic, hematologic or teratogenic toxicity.

Open Lacosamide in the interactive console ↗

Memory aids: interaction avatars

Lacosamide Box: minimal PK interactions avatar mnemonic
Box: minimal PK interactions

Open Lacosamide in the interactive console ↗